Truist analyst David MacDonald lowered the firm’s price target on CVS Health to $98 from $103 but keeps a Buy rating on the shares. The analyst notes that while the company’s FY24 target was adjusted lower, its cash flow generation and financial flexibility remain attractive, and the stock’s valuation risk/reward is seen favorably.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CVS:
- 3 Best Stocks to Buy Now, 8/3/2023, According to Top Analysts
- CVS Health price target lowered to $86 from $89 at Barclays
- CVS Health Corp Reports Earnings: Did it Beat Estimate Forecasts?
- CVS Health (NYSE:CVS): Collect Healthy Dividends with This Stock
- Unusually active option classes on open August 2nd